Protocol Ledger

NCT05519085 · Phase III · RECRUITING

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Interventional Phase III clinical trial protocol NCT05519085 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-20 Enrollment: 810 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05519085
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)810 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05519085
Protocol FieldVerified Registry Value
NCT IdentifierNCT05519085
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment810 participants (ESTIMATED)
Registered Start Date2022-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05519085
Hospital Research SiteLocationSite Profile
Universitätsklinikum BonnBonn, GermanyOpen Hospital Dossier ->
Universitaetsklinikum Hamburg EppendorfHamburg, GermanyOpen Hospital Dossier ->
Universitaetsklinikum TuebingenTübingen, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI